Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600201609> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2600201609 abstract "Background: There are no previous reports of paliperidone palmitate’s (PP) long term tolerability or pharmacokinetics of the highest dose in patients with schizophrenia. This study evaluates safety and tolerability, as well as pharmacokinetics, of the highest marketed dose of PP (150 mg eq. [234 mg]) in stable patients with schizophrenia over a 1-year period.Methods: In this 1-year prospective study, eligible patients (aged 18-65 years; Positive and Negative SyndromeScale’s total score ≤ 70) received an initial deltoid injection of PP 150 mg eq. The second injection one week later and subsequent once-monthly injections were deltoid or gluteal. All injections were to be PP 150 mg eq. Patientswilling to participate in intensive pharmacokinetic sampling were classified as Treatment A. Patients unwilling to undergo intensive pharmacokinetic sampling or unable to tolerate the 150 mg eq. dose (consequently receivingflexible doses of 50, 100 or 150 mg eq.) were classified as Treatment B.Results: Of the 212 patients (safety analysis set), 73% were men; 45% white; 20% black; 34% Asians; mean (SD) age41 (10.2) years, and mean (SD) baseline Positive and Negative Syndrome Scale total score 54.9 (9.03). A total of 53% (n = 113) patients completed the study and 104 received PP 150 mg eq. throughout. Mean (SD) mode dose of PPwas 144.8 (19.58) mg eq. The dosing initiation regimen resulted in rapidly achieved and maintained therapeuticpaliperidone levels over the study (average concentrations during the dosing interval were 34.7, 40.0, and 47.8 ng/mL after the 2nd, 8th, and 14th injection respectively). Most frequent (≥ 10%) treatment-emergent adverse eventswere nasopharyngitis (n = 37), insomnia (n = 32), injection-site pain (n = 32), headache (n = 28), and tachycardia (n= 27). Akathisia (n = 19) and tremor (n = 11) were the most common extrapyramidal adverse events. 33 patients had an SAE and 27 discontinued due to treatment-emergent adverse events. No deaths were reported. Mean (SD)weight change from baseline was 2.5 (5.41) kg at endpoint. Patients’ psychoses remained stable.Conclusions: Safety results after one-year therapy with the highest available dose of once-monthly paliperidonepalmitate were consistent with results from previous studies, with no new concerns noted. Plasma concentrationswere within the expected range." @default.
- W2600201609 created "2017-04-07" @default.
- W2600201609 creator A5006653866 @default.
- W2600201609 creator A5027328657 @default.
- W2600201609 creator A5043115868 @default.
- W2600201609 creator A5047362217 @default.
- W2600201609 creator A5054613770 @default.
- W2600201609 creator A5058716290 @default.
- W2600201609 creator A5074818783 @default.
- W2600201609 creator A5086849309 @default.
- W2600201609 creator A5021135425 @default.
- W2600201609 date "2012-01-01" @default.
- W2600201609 modified "2023-09-24" @default.
- W2600201609 title "A one-year prospective study of the safety,tolerability and pharmacokinetics of the highestavailable dose of paliperidone palmitate inpatients with schizophrenia" @default.
- W2600201609 hasPublicationYear "2012" @default.
- W2600201609 type Work @default.
- W2600201609 sameAs 2600201609 @default.
- W2600201609 citedByCount "0" @default.
- W2600201609 crossrefType "journal-article" @default.
- W2600201609 hasAuthorship W2600201609A5006653866 @default.
- W2600201609 hasAuthorship W2600201609A5021135425 @default.
- W2600201609 hasAuthorship W2600201609A5027328657 @default.
- W2600201609 hasAuthorship W2600201609A5043115868 @default.
- W2600201609 hasAuthorship W2600201609A5047362217 @default.
- W2600201609 hasAuthorship W2600201609A5054613770 @default.
- W2600201609 hasAuthorship W2600201609A5058716290 @default.
- W2600201609 hasAuthorship W2600201609A5074818783 @default.
- W2600201609 hasAuthorship W2600201609A5086849309 @default.
- W2600201609 hasConcept C112705442 @default.
- W2600201609 hasConcept C118552586 @default.
- W2600201609 hasConcept C126322002 @default.
- W2600201609 hasConcept C197934379 @default.
- W2600201609 hasConcept C2776412080 @default.
- W2600201609 hasConcept C2777126507 @default.
- W2600201609 hasConcept C2777288759 @default.
- W2600201609 hasConcept C2778375690 @default.
- W2600201609 hasConcept C2779727114 @default.
- W2600201609 hasConcept C2780135775 @default.
- W2600201609 hasConcept C2780494398 @default.
- W2600201609 hasConcept C2781413609 @default.
- W2600201609 hasConcept C2908997079 @default.
- W2600201609 hasConcept C42219234 @default.
- W2600201609 hasConcept C71924100 @default.
- W2600201609 hasConceptScore W2600201609C112705442 @default.
- W2600201609 hasConceptScore W2600201609C118552586 @default.
- W2600201609 hasConceptScore W2600201609C126322002 @default.
- W2600201609 hasConceptScore W2600201609C197934379 @default.
- W2600201609 hasConceptScore W2600201609C2776412080 @default.
- W2600201609 hasConceptScore W2600201609C2777126507 @default.
- W2600201609 hasConceptScore W2600201609C2777288759 @default.
- W2600201609 hasConceptScore W2600201609C2778375690 @default.
- W2600201609 hasConceptScore W2600201609C2779727114 @default.
- W2600201609 hasConceptScore W2600201609C2780135775 @default.
- W2600201609 hasConceptScore W2600201609C2780494398 @default.
- W2600201609 hasConceptScore W2600201609C2781413609 @default.
- W2600201609 hasConceptScore W2600201609C2908997079 @default.
- W2600201609 hasConceptScore W2600201609C42219234 @default.
- W2600201609 hasConceptScore W2600201609C71924100 @default.
- W2600201609 hasLocation W26002016091 @default.
- W2600201609 hasOpenAccess W2600201609 @default.
- W2600201609 hasPrimaryLocation W26002016091 @default.
- W2600201609 hasRelatedWork W1948877773 @default.
- W2600201609 hasRelatedWork W1983355191 @default.
- W2600201609 hasRelatedWork W2019932021 @default.
- W2600201609 hasRelatedWork W2066441931 @default.
- W2600201609 hasRelatedWork W2116458765 @default.
- W2600201609 hasRelatedWork W2124097898 @default.
- W2600201609 hasRelatedWork W2140000974 @default.
- W2600201609 hasRelatedWork W2169470992 @default.
- W2600201609 hasRelatedWork W2188898607 @default.
- W2600201609 hasRelatedWork W2364864305 @default.
- W2600201609 hasRelatedWork W2373942331 @default.
- W2600201609 hasRelatedWork W2407358499 @default.
- W2600201609 hasRelatedWork W2466817500 @default.
- W2600201609 hasRelatedWork W2471246678 @default.
- W2600201609 hasRelatedWork W2553099295 @default.
- W2600201609 hasRelatedWork W3038782863 @default.
- W2600201609 hasRelatedWork W3131184825 @default.
- W2600201609 hasRelatedWork W2332383224 @default.
- W2600201609 hasRelatedWork W2776819133 @default.
- W2600201609 hasRelatedWork W3125607981 @default.
- W2600201609 isParatext "false" @default.
- W2600201609 isRetracted "false" @default.
- W2600201609 magId "2600201609" @default.
- W2600201609 workType "article" @default.